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Usefulness of the SF-36 Health Survey in
screening for depressive and anxiety
disorders in rheumatoid arthritis
Faith Matcham1*, Sam Norton2, Sophia Steer3 and Matthew Hotopf1
Abstract
Background: This study aimed to assess the accuracy of the Short-Form Health Survey (SF-36) mental health subscale
(MH) and mental component summary (MCS) scores in identifying the presence of probable major depressive or
anxiety disorder in patients with rheumatoid arthritis.
Methods: SF-36 data were collected in 100 hospital outpatients with rheumatoid arthritis. MH and MCS scores were
compared against depression and anxiety data collected using validated measures as part of routine clinical practice.
Sensitivity and specificity of the SF-36 were established using receiver operating characteristic (ROC) curve analysis,
and area under the curve (AUC) compared the performance of the SF-36 components with the 9-item Patient Health
Questionnaire (PHQ9) for depression and the 7-item Generalised Anxiety Disorder (GAD7) questionnaire for anxiety.
Results: The MH with a threshold of ≤52 had sensitivity and specificity of 81.0 and 71.4 % respectively to detect
anxiety, correctly classifying 73.5 % of patients with probable anxiety disorder. A threshold of ≤56 had sensitivity and
specificity of 92.6 and 73.2 % respectively to detect depression, correctly classifying 78.6 % of patients, and the same
threshold could also be used to detect either depression or anxiety with a sensitivity of 87.9 %, specificity of 76.9 % and
accuracy of 80.6 %. The MCS with a threshold of ≤35 had sensitivity and specificity of 85.7 and 81.9 % respectively to
detect anxiety, correctly classifying 82.8 % of patients with probable anxiety disorder. A threshold of ≤40 had sensitivity
and specificity of 92.3 and 70.2 % respectively to detect depression, correctly classifying 76.3 % of patients. A threshold
of ≤38 could be used to detect either depression or anxiety with a sensitivity of 87.5 %, specificity of 80.3 % and
accuracy of 82.8 %.
Conclusion: This analysis may increase the utility of a widely-used questionnaire. Overall, optimal use of the SF-36 for
screening for mental disorder may be through using the MCS with a threshold of ≤38 to identify the presence of
either depression or anxiety.
Keywords: Anxiety, Depression, SF-36, Rheumatoid Arthritis
Background
Rheumatoid arthritis (RA) is a chronic, painful, pro-
gressive condition, which has a substantial impact on
patients’ quality-of-life (QoL) [1]. The prevalence of
depression in this condition is high, with a recent
meta-analysis [2] revealing that an estimated 38.8 %
of patients screen positive for probable major depres-
sive disorder (pMDD) according to the 9-item Patient
Health Questionnaire (PHQ9; [3]). Common mental
disorders such as pMDD or probable generalised
anxiety disorder (pGAD) can have implications for
long-term health outcomes; depression and anxiety
are associated with increased fatigue [4], impaired
long-term disease activity and physical disability [5],
and reduced treatment efficacy [6].
Despite its prevalence and importance, mental health
is rarely measured either in rheumatological research or
in clinical practice, reported as an outcome in less than
8 % of published research [7]. QoL is more frequently
measured (in 19 % of studies), most often with the
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Short-Form Health Survey (SF-36 [8]) [7]. The SF-36
has been extensively validated as a measure of QoL in
multiple populations and is the most widely used and
evaluated QoL outcome measure [9]. The SF-36 consists
of 8 domains, which assess physical function (PF), role
physical (RP), bodily pain (BP), global health (GH),
vitality (VI), social function (SF), role emotional (RE)
and mental health (MH). Scores on these subscales can
also be combined to create two higher-order summary
scores: the physical component summary (PCS) and
mental component summary (MCS). The PCS is
calculated by positively weighting the 4 physical
subscales (PF, RP, BP and GH), and by negatively
weighting the psychological subscales (VI, SF, RE and
MH). Conversely, the MCS is created by positively
weighting the psychological subscales and negatively
weighting the physical subscales.
There are several similarities between the SF-36 MH
subscale and typical depression and anxiety screening
questionnaire. Items relating to low mood (“Have you
felt downhearted and low?”), tiredness (“Did you feel
tired?”), nerves (“Have you been a very nervous person”)
and restlessness (“Did you have a lot of energy”) are
comparable to items such as “Feeling down, depressed
or hopeless” (PHQ9 item 2), “Feeling tired or having
little energy” (PHQ9 item 4), “Feeling nervous, anxious
or on edge” (GAD7 item 1) and “Being so restless that it
is hard to keep still” (GAD7 item 5). Additionally, the
weighting of other QoL domains introduced when
combining subscale scores for the MCS include other
depression and anxiety symptoms, such as psycho-
somatic symptomatology and emotional interference
with daily activities.
Validating the MH and MCS constructs within the SF-
36 as screening tools for depression and anxiety may
add extra utility to a questionnaire which is already
frequently used for research purposes, and could also
provide additional room for interrogation in clinical trial
datasets which measure QoL but not mental health. The
identification of useful thresholds can also have implica-
tions for implementing change in clinical practice. For
example, patients attending general outpatient ap-
pointment at King’s College Hospital NHS Foundation
Trust are required to complete the PHQ9 and GAD7
along with other patient reported outcomes, such as
pain and fatigue visual analogue scales (VAS), and the
Health Assessment Questionnaire (HAQ [10]) [11],
on tablet devices while they wait for their appoint-
ment. The results of these assessments are made
available immediately on their electronic health
record, with advice for onward referral if required
[11]. To date, the SF-36 MH and MCS scores have
been validated as screening tools for depression and
anxiety in an elderly population [12], however a
similar validation process has yet to be performed in
an RA sample.
We aimed to: 1) examine the relationships between
MH and MCS SF-36 domains and depression, anxiety,
and indicators of disease severity; 2) assess the accuracy
of the MH and MCS SF-36 domains in identifying the
presence of pMDD and pGAD, and describe the sensitiv-
ity and specificity of cut-off scores in the SF-36 MH and
MCS in screening for psychological disorder; and 3) to
recommend the most appropriate threshold with which
to identify pMDD, pGAD, or presence of any psycho-
logical disorder (pMDD or pGAD).
Method
Setting
Data were collected using questionnaires administered
to consecutive RA outpatients attending outpatient
appointments at King’s College Hospital, an inner city
hospital.
Eligibility criteria
In order to be eligible to participate in this study several
inclusion and exclusion criteria applied. Inclusion
criteria were: 1) Having sufficient English to complete
the questionnaire, or having at translator present to as-
sist; 2) Able to give informed consent, i.e. no substantial
learning disability or dementia. The following exclusion
criteria were applied: 1) No clinic data collected within
an appropriate timeframe (same day for psychological
variables, ± 3 months for disease activity and disability
measures); 2) Severe disability such as blindness or
extreme frailty precluding the ability to answer
independently.
Procedure
Consecutive patients attending outpatient appointments
were introduced by their clinicians to the researcher,
who then confirmed eligibility and provided patients
with the study information sheet. This information sheet
explained the purpose of the research project, and
confirmed that all responses would remain anonymous
and be analysed in a confidential manner. Patients were
also informed that they would be free to withdraw at
any time.
Consenting participants were asked to provide their
hospital number and asked to complete the SF-36.
Patients were asked to either complete the SF-36
questionnaire before leaving the hospital, or were pro-
vided with a stamped addressed envelope to complete
the questionnaire at home.
The SF-36 were combined with data collected routinely
in clinic. This clinical data includes assessment of disease
activity (DAS-28), and patient reported outcomes including:
physical disability, pain and fatigue, as well as depression
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and anxiety. Every patient attending an outpatient
appointment is asked to complete these patient-
reported outcomes as part of their pre-appointment
assessments. Patients can choose not to complete
these assessments. To be eligible for inclusion in the
current analysis, clinic data had to be collected on
the same day as the SF-36, to ensure SF-36 data rep-
resented current mood and physical health. Hospital
numbers were used to link questionnaire data with
clinical data, and data were pseudonymised (with
hospital numbers replaced with study identification
numbers) by an independent database manager before
release to the researcher. This procedure was
approved by the Midlands National Research Ethics
Service Committee (reference: 14/WM/0173).
Recruitment
Data were collected between July 2014 and February
2015, on one day per week. This day was consistent
across the recruitment period, as it had previously been
identified as having several dedicated RA clinics running,
therefore likely to yield the more eligible patients than
other days of the week.
The target sample size was set at 100. This decision
was based on the accuracy with which the area under
the ROC curve (AUC) would be estimated. Specifically,
for an AUC of 80 % or higher, width of the 95 % confi-
dence interval would be no larger than +/− 8 %, which
was deemed acceptable.
Outcome measures
Depression
Depression was measured routinely in clinic using the 9-
item Patient Health Questionnaire (PHQ9 [3]), which has
been recommended by the National Institute for Health
and Care Excellence (NICE) for use in adult patients with
chronic physical health problems [13]. Probable major
depressive disorder (pMDD) was defined as scoring “more
than half the days” or “nearly every day” within the last
two weeks on at least one of the first two items of the
PHQ-9 (low mood and anhedonia), and on at least five
out of all nine symptoms. This categorical algorithm for
identifying pMDD with the PHQ9 has 83 % (95 % CI: 72–
91 %) sensitivity and 90 % (95 % CI: 87–93 %) specificity
when validated against the “gold standard” Structured
Clinical Interview for DSM-IV for identifying pMDD, and
has an overall accuracy of 89 % (95 % CI: 86–92 %) [14].
Anxiety
Anxiety was measured routinely in clinic using the 7-item
Generalised Anxiety Disorder (GAD7) questionnaire. A
score of 10 or more on the GAD7 has 89 % (95 % CI: 73–
98 %) sensitivity and 82 % (95 % CI: 79–84 %) specificity
for identifying the presence of probable generalised
anxiety disorder (pGAD), when compared to psychiatric
interviews [15].
Disease variables
Disease activity was quantified using the 28-joint disease
activity score (DAS28). This DAS28 is recommended by
all major RA guidelines and is considered to be the
gold-standard indicator of disease activity [16]. The
DAS28 takes into account subjective and objective
markers of disease severity: erythrocyte sedimentation
rate (ESR) and a clinician-recorded swollen joint count
(SJC) provide objective indication of inflammation;
patient-reported tender joint count (TJC) and a patient
global assessment (PGA) provide subjective elements of
disease activity. This are combined and weighted to form
an overall DAS28 score, with higher scores indicating
worsened disease activity. A scores of ≤2.6 would
suggest the patient is in a state of remission; a score of
2.6–3.2 would suggest low disease activity; scores
between 3.2 and 5.1 would indicate moderate disease ac-
tivity; and scores of over 5.1 would suggest high disease
activity [17].
The HAQ [10] is a patient-reported measure of phys-
ical disability. It contains questions relating to 8 domains
of activities of daily living: dressing and grooming; rising;
eating; walking; hygiene; reach; gripping and opening
things; and daily activities. Scoring for each section
ranged between 0 (“without any difficulty”) to 3 (“unable
to do”), and total scores are on a scale of 0–3, with
higher scores indicating higher levels of disability.
Pain and fatigue data were each collected via 0–100
visual analogue scales, with higher scores indicating
increased levels of pain/fatigue.
SF-36
SF-36 subscales were calculated according to the SF-36
manual [18], resulting in 8 subscale scores: physical
function (PF), role physical (RP), bodily pain (BP), gen-
eral health (GH), vitality (VI), social functioning (SF),
role emotional (RE), and mental health (MH). Physical
component summary (PCS) and mental component
(MCS) scores were calculated by norming subscale
scores against population scores obtained from a norma-
tive UK dataset [19]. Normed subscale results were then
weighted appropriately to calculate PCS and MCS totals,
where a score of 50 represents the mean of the UK
population (SD10).
Statistical analyses
Linear regression analyses examined any differences in
mental and physical health between patients who partici-
pated in the study and patients who did not, to assess
for potential selection bias. Patients who did not have
clinical data collected within the specified timeframe
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(same day for psychological variables, ± 3 months for
disease activity and disability measures), had their next
closest clinical data included in this analysis only, to test
for significant differences in disease state between those
recruited and the remaining clinical population. Pearson’s
correlation analyses will assess the associations between
PHQ9 depression scores, the SF-36 mental health subscale
and mental component summary and: age; anxiety;
disease duration; fatigue; pain; HAQ; DAS28 and its com-
ponents TJC, SJC, ESR and PGA; CRP; BMI; the SF-36
subscales PF, RP, BP, GH, VI, RE, SF and PCS; and illness
perceptions of consequence, timeline, personal control,
treatment control, identity, concern, coherence and emo-
tional representation.
Main analysis included sensitivity, specificity, predict-
ive value and likelihood ratio assessment, along with
ROC curve analysis to combine sensitivity and specifi-
city. The AUC was used to compare the performance of
the MH and MCS SF-36 components with PHQ9 to de-
fine depression and GAD7 to identify anxiety. Optimal
thresholds for identifying depression with the MH and
MCS were found through identifying the threshold
which provided the highest level of sensitivity, with
the least sacrifice in specificity. Positive and negative
likelihood ratios described the accuracy of the SF-36
in detecting cases of pMDD and pGAD, with positive
likelihood ratio thresholds of >10, 5–10, 2–5 and 1–2
indicating large, moderate, small (important), small
(unimportant) changes in probability, and negative
likelihood ratio thresholds of <0.1, 0.1–0.2, 0.2–0.5
and 0.5–1.0 indicating large, moderate, small (important),
small (unimportant) changes in probability [20]. Analyses
were conducted using STATA v11.
Results
A total of 244 individual patients attended appointments
throughout the recruitment period. Of these, 119 (48.8 %)
met all eligibility criteria and were invited to participate.
Of the patients who did not meet eligibility criteria
(N = 28): 2 had severe learning disabilities and could
not provide informed consent; 6 patients were too
disabled to answer independently; and 10 patients did
not speak enough English and did not have a transla-
tor present. Nine eligible patients (7.6 %) were unable
to be approached due to time constraints in the
clinic. Ten eligible patients (8.4 %) declined to partici-
pate. A total of 107 patients attending appointments
did not have clinic data collected within the previ-
ously specified eligible timeframe (same day for psy-
chological variables, ± 3 months for disease activity
and disability measures), therefore precluding them
from meaningful comparison with the SF-36 data (as
SF-36 data would not represent current mood state,
or recent disease status). In total, 100 patients were
successfully recruited, yielding a total participation
rate of 84.0 % (Fig. 1).
Table 1 shows the mean scores of pertinent available
mental and physical variables across all patients attending
appointments during the recruitment period. In compari-
son to patients who were recruited, ineligible patients
were significantly older (p = 0.007), and had higher
levels of pain (p = 0.03), disability (p = 0.01), and
DAS28 (p = 0.02). Neither depression nor anxiety
levels significantly differed across participation
statuses.
Description of sample
Table 2 reports the descriptive statistics for the study
sample. A total of 27 % of patients screened positive for
pMDD and 22.5 % for pGAD. The mean disease
duration was 6.5 years, and the mean DAS28 was 3.9
(SD = 1.7). On a scale of 0–100, where higher scores
represent better quality-of-life, the mean MH and MCS
scores were 59.7 (SD = 23.4) and 41.7 (SD = 12.5)
respectively. Overall, the sample had moderate disease
activity (DAS-28 m = 3.9, SD = 1.7).
Associations between variables
Table 3 summarises the correlational relationships
between continuous variables.
There were several commonalities in associations
between depression, anxiety MH and MCS. All three
showed similar strength and direction of (or lack of )
association with fatigue, pain, disability (HAQ), TJC,
SJC, PGA, DAS28, and all SF-36 variables.
However whereas lower age was associated with in-
creased anxiety, MH and MCS, no association was found
between age and depression. Higher depression scores
were found to be associated with increased ESR, no
such association was found between ESR and anxiety
MH and MCS.
Sensitivity, specificity and receiver operating
characteristic (ROC) curves for probable Major Depressive
Disorder (pMDD)
The results of the ROC curve are shown in Fig. 2. The
overall accuracy with which the SF-36 MH and MCS
scales identify patients with pMDD are 86.0 and 88.9 %
respectively. A full list of cut-points identified for pMDD
using the MH and MCS are provided in the Additional
file 1: Table S1.
SF-36 Mental Health (MH) subscale
A threshold of ≤56 provides a sensitivity of 92.6 % and a
specificity of 73.2 %, correctly classifying 78.6 % of RA
patients with pMDD. This is the equivalent to a normed
MH subscale score of ≤40. The positive likelihood ratio
of 3.5 suggests a small but important increase in the
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likelihood of the presence of pMDD in the case of an
overall score ≤56. The negative likelihood ratio of 0.1
indicates a moderate decrease in the likelihood of
pMDD in the case of an overall score of >56.
SF-36 Mental Component Summary (MCS)
A cut-point of 40 on the normed MCS provides a sensi-
tivity of 92.3 % and a specificity of 70.2 %. This threshold
correctly classified 76.3 % of RA patients with pMDD. A
positive likelihood ratio of 3.1 suggests a small but
important increase in the likelihood of pMDD being
present, and the negative likelihood ratio of 0.1 suggests
a moderate decrease in the likelihood of pMDD in the
case of an MCS score of >40.
Sensitivity, specificity and receiver operating
characteristic (ROC) curves for probable Generalised
Anxiety Disorder (pGAD)
The results of the ROC curve are shown in Fig. 3. The
overall accuracy with which the SF-36 MH and MCS
Table 1 Mean scores for mental and physical health variables across attending patients
Recruited (N = 100) Not recruited (N = 19) No clinic data within time-frame (N = 107) Ineligible (N = 18)
M (SD) M (SD) M (SD) M (SD)
Age 55.5 (15.9) 53.8 (16.8) 55.9 (15.4) 66. 4 (14.3)**
Depression (0–6) 2.2 (2.0) 2.4 (2.0) 2.1 (1.7) 2.0 (1.2)
Anxiety (0–6) 2.0 (1.8) 1.8 (1.7) 1.7 (1.8) 2.3 (2.4)
Pain (0–100) 50.5 (25.9)* 58.3 (19.0) 49.2 (26.3) 70.4 (21.3)*
Fatigue (0–100) 54.4 (25.8) 59.9 (16.6) 50.0 (24.0) 67.0 (18.7)
HAQ 1.3 (0.8)* 1.7 (0.6) 1.2 (0.8) 2.2 (0.7)*
DAS28 3.9 (1.7)* 3.4 (1.3) 3.3 (1.6) 4.9 (1.4)*
*p < 0.5, **p < 0.01. Bold text denotes significantly different scores when compared to the recruited group. HAQ health assessment questionnaire. DAS28 28-joint
disease assessment schedule
Fig. 1 Flow chart of study recruitment
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Table 3 Pearson’s correlation analysis of bivariate associations
Depression Anxiety MH MCS
Depression –
Anxiety 0.59*** –
MH −0.71*** −0.70*** –
MCS −0.66*** −0.63*** 0.91*** –
Age −0.07 −0.23* −0.29** −0.32**
Disease duration 0.04 0.04 0.07 0.06
Fatigue 0.35*** 0.32** 0.39*** 0.39***
Pain 0.38*** 0.31** 0.36*** 0.30**
HAQ 0.57*** 0.35** 0.46*** 0.37**
TJC 0.27* 0.23* 0.29** 0.31**
SJC 0.01 0.05 0.01 0.08
ESR 0.28** 0.10 0.17 0.18
PGA 0.26* 0.27* 0.27* 0.25*
DAS28 0.35** 0.31** 0.32** 0.31**
SF-36
PF −0.48*** −0.36** 0.41*** 0.34**
RP −0.48*** −0.30** 0.46*** 0.51***
BP −0.47*** −0.31** 0.39*** 0.41***
GH −0.34*** −0.48*** 0.58*** 0.60***
VI −0.49*** −0.40*** 0.60*** 0.72***
RE −0.49*** −0.42*** 0.63*** 0.82***
SF −0.63*** −0.48*** 0.58*** 0.67***
PCS −0.42*** −0.28** 0.25* 0.24*
MH SF-36 mental health subscale, MCS SF-36 mental component summary,
HAQ health assessment questionnaire, TJC Tender Joint count, SJC swollen
joint count, ESR erythrocyte sedimentation rate, PGA patient global
assessment, DAS28 28-joint disease activity score, CRP C-reactive protein, BMI
body mass index, SF-36 short form 36, PF physical function, RP role physical,
BP bodily pain, GH global health, VI vitality, RE role emotional, SF social functioning,
PCS SF-36 physical component summary. Depression measured via PHQ2
(score range 0–6). Anxiety measured via GAD2 (score range 0–6)
*p < 0.05. **p < 0.01. ***p < 0.001
Table 2 Description of study sample
Variable Category/Range N % M SD
Total Sample 100
Age 24–87 55.5 15.9
Female gender 81 81.0 %
Ethnicity White British 44 44.0 %
Asian 10 10.0 %
Black 20 20.0 %
White Other 14 14.0 %
Other 12 12.0 %
Mental Health
Depression
Total
0–6 2.2 2.0
Depression
Category
No symptoms 57 57.0 %
Some symptoms 16 16.0 %
pMDD 27 27.0 %
Anxiety Total 0–6 2.0 1.8
Anxiety
Category
No symptoms 63 64.3 %
Some symptoms 13 13.3 %
pGAD 22 22.5 %
Psychological
Distress
pGAD or pMDD 34 34.0 %
Physical Health
Disease duration
(years)
0.8–34.9 6.5 6.4
Fatigue 0–100 54.4 25.8
Pain 0–100 50.5 25.9
HAQ 0–3 1.3 0.8
TJC 0–28 5.2 6.4
SJC 0–16 2.0 2.8
ESR 1–121 24.1 23.6
PGA 1–100 49.2 28.2
DAS28 0.1–7.5 3.9 1.7
SF-36 (normed subscale scores shown in brackets)
Physical
Function
(PF)
0–100 (13.1–56.8) 42.3 (31.6) 28.9 (12.6)
Role Physical
(RP)
0–100 (26.0–55.6) 28.6 (34.4) 39.5 (11.7)
Bodily Pain
(BP)
0–90 (18.0–56.2) 36.5 (33.5) 24.1 (10.2)
Global Health
(GH)
0–100 (14.2–63.8) 38.3 (33.2) 21.5 (10.7)
Vitality (VI) 0–85 (20.7–61.5) 36.5 (38.2) 23.2 (11.1)
Role
Emotional
(RE)
0–100 (25.4–55.7) 35.7 (36.2) 42.5 (12.9)
Table 2 Description of study sample (Continued)
Social
Functioning
(SF)
0–100 (12.6–57.3) 55.7 (37.5) 30.6 (13.7)
Mental
Health (MH)
0–100 (8.4–64.0) 59.7 (41.6) 23.4 (13.0)
PCS 13.7–55.0 31.7 9.7
MCS 18.8–69.0 41.7 12.5
pMDD probable major depressive disorder, pGAD probable generalised anxiety
disorder, HAQ health assessment questionnaire, TJC tender joint count, SJC
swollen joint count, ESR erythrocyte sedimentation rate, PGA patient global
assessment, DAS-28 28-joint disease activity scale, PCS SF-36 physical component
summary, MCS mental component summary
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scales identify patients with pMDD are 89.3 and 88.1 %
respectively. A full list of cut-points identified for pGAD
using the MH and MCS are provided in the Additional
file 1: Table S1.
SF-36 Mental Health (MH) subscale
A threshold of ≤52 provides a sensitivity of 81.0 % and a
specificity of 71.4 %, correctly classifying 73.5 % of RA
patients with pGAD. This is the equivalent to a normed
MH subscale score of ≤37. The positive likelihood ratio
of 2.8 suggests a small but important increase in the
likelihood of the presence of pGAD in the case of an
overall score ≤52. The negative likelihood ratio of 0.3 in-
dicates a small but important decrease in the likelihood
of pMDD in the case of an overall score of >52.
SF-36 Mental Component Summary (MCS)
A cut-point of 35 on the normed MCS provides a sensi-
tivity of 85.7 % and a specificity of 81.9 %. This threshold
correctly classified 83 % of RA patients with pGAD. A
Fig. 2 ROC for pMDD with MH and MCS SF-36 scores
Fig. 3 ROC for pGAD with MH and MCS SF-36 scores
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positive likelihood ratio of 4.7 suggests a small increase in
the likelihood of pGAD being present, and the negative
likelihood ratio of 0.2 suggests a moderate decrease in the
likelihood of pGAD in the case of an MCS score of >35.
Sensitivity, specificity and receiver operating characteristic
(ROC) curves for any mental disorder (pMDD or pGAD)
The results of the ROC curve are shown in Fig. 4. The
overall accuracy with which the SF-36 MH and MCS
scales identify patients with any mental disorder (pMDD
or pGAD) are 89.4 % and 89.5 % respectively. A full list
of cut-points identified for pMDD or pGAD using the
MH and MCS are provided in the Additional file 1:
Table S1.
SF-36 Mental Health (MH) subscale
A threshold of ≤56 provides a sensitivity of 87.9 % and a
specificity of 76.9 %, correctly classifying 80.6 % of RA
patients with pMDD or pGAD. This is the equivalent to
a normed MH subscale score of ≤40. The positive likeli-
hood ratio of 3.8 suggests a small but important increase
in the likelihood of the presence of mental disorder in
the case of an overall score ≤56. The negative likelihood
ratio of 0.2 indicates a moderate decrease in the likeli-
hood of any mental disorder in the case of an overall
score of >56.
SF-36 Mental Component Summary (MCS)
A cut-point of 38 on the normed MCS provides a sensi-
tivity of 87.9 % and a specificity of 76.9 %. This threshold
correctly classified 82.8 % of RA patients with any men-
tal disorder. A positive likelihood ratio of 4.4 suggests a
small but important increase in the likelihood of pMDD
or pGAD being present, and the negative likelihood ratio
of 0.2 suggests a moderate decrease in the likelihood of
pMDD or pGAD in the case of an MCS score of >38.
Discussion
The results of this analysis suggest that the SF-36 can be
used to determine the presence of pMDD, pGAD, or
general psychological disorder, and potential thresholds
have been suggested for these diagnoses. However opti-
mal use of the SF-36 for screening for mental disorder
may be by utilising a threshold of ≤38 on the MCS, to
identify the presence of any psychological disorder. This
threshold had good sensitivity (88 %) and specificity
(80 %), and correctly classified 83 % of patients with
either pMDD or pGAD. This can be compared to sensi-
tivity and specificity of 95 and 66 % respectively for the
NICE-recommended questions for identifying depression
in patients with chronic physical health problems [13].
A similar validation study in an elderly population
identified 42 as an appropriate MCS threshold to iden-
tify significant psychological distress [12]. Our identified
threshold of 38 is comparable to this. As the MCS is
normed, with a score of 50 (standard deviation = 10)
representing the UK population, this threshold identifies
patients with a score of 1 standard deviation below the
population mean (scoring in the bottom 16 % of the
population) as being at risk of pMDD or pGAD.
There are several elements to take into consideration
when evaluating the research process described. The pri-
mary limitation is the lack of a “gold-standard” depression
measure with which to validate the SF-36 domains.
Fig. 4 ROC for pMDD or pGAD with MH and MCS SF-36 scores
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Employing a psychologist or psychiatrist to diagnose
the presence of depression was beyond the financial
and time restrictions present. We therefore relied on
the measurement already taken as part of routine
clinical practice, which were the PHQ9 and GAD7.
Given their sensitivity and specificity of these measures
against gold standard diagnostic criteria, we can expect an
increase in detection of false positives. For example, if the
true prevalence of depression is 20 %, and assuming an
accuracy of 89 % for the PHQ9 [14] and GAD [15], our
detected MCS accuracy for pMDD of 83 % would
translate into a lower bound for the accuracy of 74 % for
detecting true MDD. This assumed the two screening
tools are independent, so it is almost certain that true
accuracy is between 74 and 83 %. Although the PHQ9 and
GAD7 are well-validated themselves [14, 15] future
research is required to replicate the findings of this study
using a gold-standard psychiatric interview against which
to validate the MCS and MH scales of the SF-36. However
this research has increased the utility of this widely used
questionnaire and provides interesting scope for further
validation and secondary analyses of existing datasets.
An additional consideration is the representativeness
of our sample. As described in our methods section,
patients who were unable to give consent due to learn-
ing disabilities or dementia, or who were too disabled to
answer independently, we not considered eligible for
inclusion in this study. This selection bias resulted in
ineligible patients being significantly older, having higher
levels of pain, disability and disease activity, than
patients who were recruited for participation. The gener-
alisability of our results to the wider RA population is
questionable, although it is important to note that there
were no differences in mental health across those who
participated and those who did not.
Conclusion
Despite these shortcomings, this analysis provides a
useful first step in adding extra utility to a measurement
tool already frequently used for research purposes. The
addition of regular HRQoL measurement to routine RA
clinical care would be beneficial, as QoL is a key outcome
of importance to patients [21], and doing so would also
support the need for embedded mental health care within
rheumatological management practice.
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PHQ9 or GAD7 criteria. Description of data – summary of all potential
thresholds identified for indicating presence of pMDD or pGAD, along
with relevant sensitivity and specificity data. (DOCX 17 kb)
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